—To determine the safety and immunogenicity of Haemophilus influenzae type b conjugate vaccine in children with sickle cell disease.
—Prospective, nonrandomized, nonblinded study.
—Hospital-based, comprehensive sickle cell center.
—Children with sickle cell disease aged 18 months to 18 years who were previously unvaccinated or had an inadequate or waning response to H influenzae type b polysaccharide vaccine.
—Consecutive eligible patients.
—Vaccination and observation for adverse effects. Blood samples were taken before and 1 to 2 and 6 months after vaccination to measure anticapsular antibody levels.
Measurements and Results.
—Vaccination was well tolerated. One hundred percent and 96% of the 31 immunized children had postvaccination anticapsular antibody concentrations of greater than 0.15 and 1.0 mg/L, respectively. Six months after vaccination, 100% and 89% of children had these antibody concentrations.
—H influenzae type b conjugate vaccines are safe and highly immunogenic in children with sickle cell disease. It is likely that these vaccines will be protective against invasive H influenzae type b disease.(AJDC. 1992;146:340-342)
Rubin LG, Voulalas D, Carmody L. Immunogenicity of Haemophilus influenzae Type b Conjugate Vaccine in Children With Sickle Cell Disease. Am J Dis Child. 1992;146(3):340–342. doi:10.1001/archpedi.1992.02160150080026
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.